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A B S T R A C T
Background
Osteoarthritis is the most common form of joint disease and the leading cause of pain and physical disability in the elderly. Opioids
may be a viable treatment option if patients suffer from severe pain or if other analgesics are contraindicated. However, the evidence
about their effectiveness and safety is contradictory.
Objectives
To determine the effects on pain and function and the safety of oral or transdermal opioids as compared with placebo or no intervention
in patients with osteoarthritis of the hip or knee.
Search strategy
We searched CENTRAL, MEDLINE, EMBASE, and CINAHL (up to 28 July 2008), checked conference proceedings, reference lists,
and contacted authors.
Selection criteria
Studies were included if they were randomised or quasi-randomised controlled trials that compared oral or transdermal opioids with
placebo or no treatment in patients with osteoarthritis of the knee or hip. Studies of tramadol were excluded. No language restrictions
were applied.
Data collection and analysis
We extracted data in duplicate. Standardised mean differences (SMDs) and 95% confidence intervals (CI) were calculated for pain and
function, and risk ratios for safety outcomes. Trials were combined using inverse-variance random-effects meta-analysis.
Main results
Ten trials with 2268 participants were included. Oral codeine was studied in three trials, transdermal fentanyl and oral morphine in one
trial each, oral oxycodone in four, and oral oxymorphone in two trials. Overall, opioids were more effective than control interventions
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in terms of pain relief (SMD -0.36, 95% CI -0.47 to -0.26) and improvement of function (SMD -0.33, 95% CI -0.45 to -0.21). We
did not find substantial differences in effects according to type of opioid, analgesic potency (strong or weak), daily dose, duration of
treatment or follow up, methodological quality of trials, and type of funding. Adverse events were more frequent in patients receiving
opioids compared to control. The pooled risk ratio was 1.55 (95% CI 1.41 to 1.70) for any adverse event (4 trials), 4.05 (95% CI
3.06 to 5.38) for dropouts due to adverse events (10 trials), and 3.35 (95% CI 0.83 to 13.56) for serious adverse events (2 trials).
Withdrawal symptoms were more severe after fentanyl treatment compared to placebo (SMD 0.60, 95% CI 0.42 to 0.79; 1 trial).
Authors’ conclusions
The small to moderate beneficial effects of non-tramadol opioids are outweighed by large increases in the risk of adverse events. Non-
tramadol opioids should therefore not be routinely used, even if osteoarthritic pain is severe.
P L A I N L A N G U A G E S U M M A R Y
Opioids for osteoarthritis
This summary of a Cochrane review presents what we know from research about the effect of opioids on osteoarthritis.
The review shows that in people with osteoarthritis:
- Opioids moderately improve pain or physical function.
- Opioids probably cause side effects. However, we do not have precise information about rare but serious side effects.
What is osteoarthritis and what are opioids?
Osteoarthritis (OA) is a disease of the joints, such as your knee or hip. When the joint loses cartilage, the bone grows to try and repair
the damage. Instead of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can
become misshapen and make the joint painful and unstable. This can affect your physical function or ability to use your knee.
Opioids are powerful pain-relieving substances that are used for the pain of cancer or osteoarthritis. Some examples of opioids are
codeine-containing Tylenol® (1, 2, 3 and 4), hydromorphone (Dilaudid), oxycodone (Percocet, Percodan), morphine and others.
They can be taken in a pill form, as an injection, or as a patch placed on the painful area.
Best estimate of what happens to people with osteoarthritis who take Opioids
Pain
- People who took opioids rated improvement in their pain to be about 3 on a scale of 0 (no pain) to 10 (extreme pain) after 1 month.
- People who took a placebo rated improvement in their pain to be about 2 on a scale of 0 (no pain) to 10 (extreme pain) after 1 month.
Another way of saying this is:
- 35 people out of 100 who use opioids respond to treatment (35%).
- 31 people out of 100 who use placebo respond to treatment (31%).
- 4 more people respond to treatment with opioids than with placebo (difference of 4%).
Physical Function
- People who took opioids rated improvement in their physical function to be about 2 on a scale of 0 (no disability) to 10 (extreme
disability) after 1 month.
- People who took a placebo rated improvement in their physical function to be about 1 on a scale of 0 (no disability) to 10 (extreme
disability) after 1 month.
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Another way of saying this is:
- 29 people out of 100 who use opioids respond to treatment (29%).
- 26 people out of 100 who use placebo respond to treatment (26%).
- 3 more people respond to treatment with opioids than with placebo (difference of 3%).
Side effects
- 23 people out of 100 who used opioids experienced side effects (23%).
- 15 people out of 100 who used a placebo experienced side effects (15%).
- 7 more people experienced side effects with opioids than with placebo (difference of 7%).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [ Explanation]
Oral or transdermal opioids compared with placebo for osteoarthritis of the knee or hip
Patient or population: Patients with osteoarthritis of the knee or hip
Settings: Various orthopedic or rheumatology clinics
Intervention: Oral or transdermal opioids
Comparison: Placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Opioids
Pain intensity
Various pain scales.
(median follow-up: 4
weeks)
-1.8 cm change
on 10 cm VAS1
29% improvement
-2.7 cm change
(1 -0.9 cm,-1.2 to -0.7)2
44% improvement
(1 15%, 11% to 20%)3
SMD -0.36 (-0.47 to -0.26) 2268
(10)
++++
high
NNT: 25 (95% CI 19 to 34)4
Function
Various validated function
scales.
(median follow-up: 4
weeks)
-1.2 units
on WOMAC (range 0 to
10)1
21% improvement
-1.9 units on WOMAC
(1 -0.7, -1.0 to -0.5)5
34% improvement
(1 13%, 9% to 18%)6
SMD -0.33 (-0.45 to -0.21) 1794
(7)
++++
high
NNT: 30 (95% CI 22 to 46)7
Number of patients ex-
periencing any adverse
event
(median follow-up: 4
weeks)
150 per 1000 patient-
years8
233 per 1000 patient-years
(212 to 255)
RR 1.55 (1.41 to 1.70) 1080
(4)
+++O
moderate9
NNH: 12 (95% CI 10 to 16)
Number of patients who
withdrew because of ad-
verse events
(median follow-up: 4
weeks)
17 per 1000 patient-years8 69 per 1000 patient-years
(52 to 91)
RR 4.05 (3.06 to 5.38) 2403
(10)
++++
high
NNH: 19 (95% CI 13 to 29)
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Number of patients expe-
riencing any serious ad-
verse event
(median follow-up: 4
weeks)
4 per 1000 patient-years8 13 per 1000 patient-years
(3 to 54)
RR 3.35 (0.83 to 13.56) 681
(3)
++OO
low10
Little evidence of harmful
effect [NNH: not statisti-
cally significant].
Withdrawal symptoms
Short Opiate Withdrawal
Scale.
(follow-up: 8 weeks)
0.9 units
(range 0 to 3)
0.7 units
(1 0.3, 0.2 to 0.4)
69% increase
(46 to 92%)11
SMD 0.60 (0.42 to 0.79) 499
(1)
++OO
low12
No evidence-based as-
sumption could be made
for the calculation of NNH.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in
the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; SMD: Standardised mean difference; GRADE: GRADE Working Group grades of evidence (see explanations); NNT: number needed to treat; NNH: number needed
to harm.
GRADE Working Group grades of evidence
High quality (++++): Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality (+++O): Further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate.
Low quality (++OO): Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely
to change the estimate.
Very low quality (+OOO): We are very uncertain about the estimate.
1 Median reduction as observed across placebo groups in large osteoarthritis trials (see methods section, Nüesch 2009).
2 Standardised mean differences (SMDs) were back-transformed onto a 10 cm visual analogue scale (VAS) on the basis of a typical
pooled SD of 2.5 cm in large trials that assessed pain using a VAS and expressed as change based on an assumed standardised
reduction of 0.72 standard deviation units in the control group.
3 Percentage of improvement was calculated based on median observed pain at baseline across control groups of large osteoarthritis
trials of 6.1 cm on 10 cm VAS (Nüesch 2009).
4 Absolute response risks for pain in the control groups were assumed 31% (see methods section).
5 Standardised mean differences (SMDs) were back-transformed onto a standardised WOMAC disability score ranging from 0 to 10 on
the basis of a typical pooled SD of 2.1 in trials that assessed function using WOMAC disability scores and expressed as change based
on an assumed standardised reduction of 0.58 standard deviation units in the control group.
6 Percentage of improvement was calculated based on median observed WOMAC function scores at baseline across control groups of
large osteoarthritis trials of 5.6 units (Nüesch 2009).
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7 Absolute response risks for function in the control groups were assumed 26% (see methods section).
8 Median control risk across placebo groups in large osteoarthritis trials (see methods section, Nüesch 2009).
9 Downgraded (1 level) because: 4 out of 10 studies reported this outcome, possibly leading to selective outcome reporting bias.
10 Downgraded (2 levels) because: 3 out of 10 studies reported this outcome, possibly leading to selective outcome reporting bias, the
confidence interval of the pooled estimate is wide and crossed no difference.
11 Percentage of improvement was calculated based on observed withdrawal symptom scores in the placebo group of 0.39.
12 Downgraded (2 levels) because the outcome was assessed by a single trial assessing transdermal fentanyl therapy, and 8 weeks
follow-up duration considered short for this outcome.
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B A C K G R O U N D
Osteoarthritis is the most common form of joint disease and the
leading cause of pain and physical disability in the elderly (Altman
1986). It is characterised by focal areas of loss of articular cartilage
in synovial joints accompanied by subchondral bone changes, os-
teophyte formation at the joint margins, thickening of the joint
capsule andmild synovitis. Pharmacologic therapy for osteoarthri-
tis, as an alternative or in addition to other therapeutic options,
consists mainly of analgesics and nonsteroidal anti-inï¬‚ammatory
drugs (NSAIDs). However, paracetamol may be inadequate to
treat more severe, long-term pain in osteoarthritis and chronic
NSAID use may cause serious gastrointestinal and cardiovascular
adverse events. Opioids could be a viable alternative if patients
suffer from severe pain with insufficient response to conventional
treatment or if other analgesics are contraindicated (Avouac 2007).
Opioids are potent analgesics that work by targeting mainly spinal
and supraspinal opioid receptors. In addition, cellular studies sug-
gest that there are peripheral opioid receptors in inflamed os-
teoarthritic synovial tissue, which may mediate analgesic effects (
Stein 1996). The American College of Rheumatology guidelines
on management of osteoarthritis, updated in 2000, suggest that
opioids can be used as a last resort in osteoarthritis (ACR OA
2000). English guidelines propose opioids as an alternative if in-
adequate pain relief is achieved with an NSAID or paracetamol
(Eccles 1998). However, the use of strong opioids for the treat-
ment of non-cancer pain remains controversial. Concerns have
been expressed about long-term use of opioids for chronic non-
cancer pain mainly due to the risks of addiction (Von Korff 2004;
Zhang 2008).
O B J E C T I V E S
We set out to compare oral or transdermal opioidswith placeboor a
non-intervention control in terms of effects on pain and function,
safety, and addiction in patients with knee or hip osteoarthritis
(OA); and to explore whether potential variation between trials
could be explained by type of opioid, route of administration,
biases affecting individual trials, or publication bias.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials with a control
group receiving placebo or no intervention.
Types of participants
At least 75% of patients with clinically or radiologically confirmed
osteoarthritis of the knee or hip. Trials exclusively including pa-
tients with inflammatory arthritis, such as rheumatoid arthritis,
were not considered.
Types of interventions
Any type of opioid except tramadol, which is covered in a separate
Cochrane Review (Cepeda 2006).
Types of outcome measures
Primary outcomes
The main outcomes were pain and function, as currently recom-
mended for osteoarthritis trials (Altman 1996; Pham 2004). If
data on more than one pain scale were provided for a trial, we
referred to a previously described hierarchy of pain-related out-
comes (Jüni 2006; Reichenbach 2007) and extracted data on the
pain scale that was highest on this list:
1. global pain;
2. pain on walking;
3. WOMAC osteoarthritis index pain subscore;
4. composite pain scores other than WOMAC;
5. pain on activities other than walking;
6. rest pain or pain during the night;
7. WOMAC global algofunctional score;
8. Lequesne osteoarthritis index global score;
9. other algofunctional scale;
10. patient’s global assessment;
11. physician’s global assessment.
If data on more than one function scale were provided for a trial,
we extracted data according to the hierarchy:
1. global disability score;
2. walking disability;
3. WOMAC disability subscore;
4. composite disability scores other than WOMAC;
5. disability other than walking;
6. WOMAC global scale;
7. Lequesne osteoarthritis index global score;
8. other algofunctional scale;
9. patient’s global assessment;
10. physician’s global assessment.
If pain or function outcomes were reported at several time points,
we extracted the measure at the end of the treatment period.
Secondary outcomes
Secondary outcomeswere the number of patients experiencing any
adverse event, patients who withdrew because of adverse events,
patients experiencing any serious adverse events, andpatients expe-
riencing symptoms of opioid dependence such as craving or phys-
ical withdrawal symptoms. Serious adverse events were defined as
events resulting in hospitalisation, prolongation of hospitalisation,
persistent or significant disability, congenital abnormality or birth
defect of offspring, life-threatening events, or death.
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Search methods for identification of studies
Electronic searches
We searched the electronic databases CENTRAL (The Cochrane
Library) (http://mrw.interscience.wiley.com/cochrane/), MED-
LINE and EMBASE through theOvid platform (www.ovid.com),
and CINAHL through EBSCOhost (all from implementation to
July 28 2008) using truncated variations of preparation names in-
cluding brand names combined with truncated variations of terms
related to osteoarthritis, all as text words. A validated method-
ologic filter for controlled clinical trials was applied (Dickersin
1994). The specific search algorithms are displayed in Appendix
1 and Appendix 2.
Searching other sources
We manually searched conference proceedings, used Science Ci-
tation Index to retrieve reports citing relevant articles, con-
tacted content experts and trialists, and screened reference lists
of all obtained articles. Finally, we searched several clinical
trial registries (www.clinicaltrials.gov, www.controlled-trials.com,
www.actr.org.au, www.umin.ac.jp/ctr) to identify ongoing trials.
The last update of the manual search was on July 28, 2008.
Data collection and analysis
Selection of studies
Two review authors independently evaluated all titles and abstracts
for eligibility (EN,AR) (see Figure 1).Disagreementswere resolved
by discussion. No language restrictions were applied. If multiple
reports described the same trial, we considered all.
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Figure 1. Study flow chart
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Data collection
Two review authors (EN, AR) extracted trial information inde-
pendently using a standardised, piloted extraction form accompa-
nied by a codebook. Disagreements were resolved by discussion.
We extracted both the generic and trade name of the experimental
intervention, the type of control used, dosage, frequency, route
of administration, duration of treatment, patient characteristics
(gender, average age and duration of symptoms, types of joints
affected), types of measures used and pain and function-related
outcomes, trial design, trial size, duration of follow up, type and
source of financial support, and publication status. When neces-
sary, means and measures of dispersion were approximated from
figures in the reports. For crossover trials, we extracted data from
the first period only. Whenever possible, we used results from an
intention-to-treat analysis. If effect sizes could not be calculated,
we contacted the authors for additional data.
Quality assessment
Two review authors (EN, AR) independently assessed randomi-
sation, blinding, and adequacy of analyses (Jüni 2001). Disagree-
ments were resolved by consensus. Two components of randomi-
sation were assessed: generation of allocation sequences and con-
cealment of allocation. Generation of sequences was considered
adequate if it resulted in an unpredictable allocation schedule;
mechanisms considered adequate include random-number tables,
computer-generated random numbers, minimisation, coin toss-
ing, shuffling cards, anddrawing lots. Trials using an unpredictable
allocation sequence were considered randomised; trials using po-
tentially predictable allocation mechanisms, such as alternation or
the allocation of patients according to date of birth, were consid-
ered quasi-randomised. Concealment of allocation was considered
adequate if patients and investigators responsible for patient se-
lection were unable to suspect before allocation which treatment
was next. Methods considered adequate include central randomi-
sation; pharmacy-controlled randomisation using identical pre-
numbered containers; and sequentially numbered, sealed, opaque
envelopes. Blinding of patients was considered adequate if experi-
mental and control preparations were explicitly described as indis-
tinguishable or if a double-dummy technique was used. Analyses
were considered adequate if all randomised patients were included
in the analysis according to the intention-to-treat principle. We
further assessed the reporting of primary outcomes, sample size
calculations, and funding source. Finally, we used GRADE to de-
scribe the quality of the overall body of evidence (Guyatt 2008;
Higgins 2008), defined as the extent of confidence into the esti-
mates of treatment benefits and harms.
Data synthesis
Continuous outcomes were summarised using standardised mean
differences (SMD), with the differences in mean values at the end
of treatment across treatment groups divided by the pooled stan-
dard deviation. If differences in mean values at the end of the treat-
ment were unavailable, differences in mean changes were used. If
some of the required data were unavailable we used approxima-
tions, as previously described (Reichenbach 2007). An SMD of
-0.20 standard deviation units can be considered a small differ-
ence between the experimental and control groups, an SMD of -
0.50 a moderate difference, and -0.80 a large difference (Cohen
1988; Jüni 2006). SMDs can also be interpreted in terms of the
percent of overlap of the experimental group’s scores with scores
of the control group. An SMD of -0.20 indicates an overlap in the
distribution of pain or function scores in about 85% of cases, an
SMD of -0.50 in approximately 67%, and an SMD of -0.80 in
about 53% of cases (Cohen 1988; Jüni 2006). On the basis of a
median pooled SD of 2.5 cm, found in large-scale osteoarthritis
trials that assessed pain using a 10 cm visual analogue scale (VAS)
(Nüesch 2009), SMDs of -0.20, -0.50, and -0.80 correspond to
approximate differences in pain scores between experimental and
control groups of 0.5, 1.25 and 2.0 cm on a 10 cm VAS. SMDs
for function were back transformed to a standardised WOMAC
disability score (Bellamy 1995) ranging from 0 to 10 on the basis
of a median pooled SD of 2.1 units observed in large-scale os-
teoarthritis trials (Nüesch 2009). Binary outcomes were expressed
as relative risks.
We used standard inverse-variance random-effects meta-analysis
to combine the trials (DerSimonian 1986). We quantified hetero-
geneity between trials using the I2 statistic (Higgins 2003), which
describes the percentage of variation across trials that is attributable
to heterogeneity rather than to chance. I2 values of 25%, 50%,
and 75% may be interpreted as low, moderate, and high between-
trial heterogeneity, although its interpretation depends on the size
and number of trials included (Rücker 2008). The association be-
tween trial size and treatment effects was investigated in funnel
plots, plotting effect sizes on the vertical axis against their stan-
dard errors on the horizontal axis. We assessed asymmetry by the
asymmetry coefficient, the difference in effect size per unit increase
in standard error (Sterne 2001) which is mainly a surrogate for
sample size, and used uni-variable, meta-regression analysis to pre-
dict treatment effects in trials as large as the largest trials included
in the meta-analysis using the standard error as the explanatory
variable (Shang 2005). We then performed analyses of the pri-
mary outcomes, pain and function, stratified by the following trial
characteristics: type of opioid, analgesic potency (strong versus
weak), route of administration (oral versus transdermal), type of
control (placebo versus no intervention), concealment of alloca-
tion (adequate versus inadequate or unclear), blinding of patients
(adequate versus inadequate or unclear), analysis in accordance
with the intention-to-treat principle (yes versus no or unclear),
trial size, funding, and duration of treatment. Fentanyl, morphine,
oxycodone, and oxymorphone were classified as strong opioids,
codeine and dextropropoxyphene as weak opioids. A cut off of 200
allocated patients was used to distinguish between small-scale and
large-scale trials. A sample size of 2 x 100 patients will yield more
than 80% power to detect a small to moderate SMD of -0.40 at a
two-sided P of 0.05, which corresponds to a difference of 1 cm on
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a 10 cm VAS between the experimental and control intervention.
A cut off of one month was used to distinguish between short-
term and long-term trials. Uni-variable, random-effects meta-re-
gression models were used to determine whether treatment effects
were affected by these factors (Thompson 1999). In addition, the
following two continuous variables at trial level were included in
uni-variable meta-regression: daily morphine equivalence dosage
and treatment duration. Morphine equivalence doses were calcu-
lated as previously described (Loeser 2001; Schug 2006): 10 mg
oral morphine was considered equivalent to 65 mg oral codeine,
2 µg/hour transdermal fentanyl, 7.5 mg oral oxycodone, and 10
mg oral oxymorphone.
We converted SMDs of pain intensity and function to odds ratios
(Chinn 2000) to derive numbers needed to treat (NNT) to cause
one additional treatment response on pain or function as com-
pared with placebo, and numbers needed to harm (NNH) to cause
one additional adverse outcome. We defined treatment response
as a 50% improvement in scores (Clegg 2006). With a median
standardised pain intensity at baseline of 2.4 standard deviation
units, observed in large osteoarthritis trials (Nüesch 2009), this
corresponds to an average decrease in scores of 1.2 standard de-
viation units. Based on the median standardised decrease in pain
scores of 0.72 standard deviation units (Nüesch 2009), we cal-
culated that a median of 31% of patients in the placebo group
would achieve an improvement of pain scores of 50% or more.
This percentage was used as the control group response rate to cal-
culate NNTs for treatment response on pain. Based on themedian
standardised WOMAC function score at baseline of 2.7 standard
deviation units and the median standardised decrease in function
scores of 0.58 standard deviation units (Nüesch 2009), 26% of pa-
tients in the placebo group would achieve a reduction in function
of 50% or more. Again, this percentage was used as the control
group response rate to calculate NNTs for treatment response on
function. The median risks of 150 patients with adverse events per
1000 patient-years, 4 patients with serious adverse events per 1000
patient-years, and 17 dropouts due to adverse events per 1000
patient-years as observed in placebo groups in large osteoarthritis
trials (Nüesch 2009) were used to calculate NNHs for safety out-
comes. All P-values are two-sided. Analyses were performed using
RevMan version 5 (Nordic Cochrane Centre, Cochrane Collab-
oration, Copenhagen) and STATA version 10.1 (StataCorp, Col-
lege Station, Texas).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
We identified 2563 potentially relevant references through our
electronic searches (Figure 1); 2484 references were excluded after
screening titles and abstracts and 79 potentially relevant references
were retrieved for full-text assessment. Ten randomised controlled
trials were included in the review. Checking reference lists and
handsearching of conference proceedings did not yield any addi-
tional trials.
Three trials evaluated weak opioids. All three compared codeine
with placebo (Kjaersgaard-Andersen 1990; Quiding 1992; Peloso
2000), one of these with paracetamol 3000 mg daily as analgesic
co-intervention administered in both the experimental and control
groups (Kjaersgaard-Andersen 1990) and another with ibupro-
fen 1200 mg daily administered in both groups (Quiding 1992).
Strong opioids were compared to placebo in seven trials. Mor-
phine was used in one trial (Caldwell 2002), oxymorphone in two
(Matsumoto 2005; Kivitz 2006), oxycodone in four (Chindalore
2005; Markenson 2005; Matsumoto 2005; Zautra 2005), and
transdermal fentanyl in one trial (Langford 2006). Fentanyl was
the only opioid applied by a transdermal route, all others were
given orally. Opioids were administered at a median daily dose of
51 mg morphine equivalents (range 13 to 160 mg).
The median treatment duration was four weeks (range 3 days
to 3 months). Trials randomised a median number of 161 pa-
tients (range 27 to 491 patients). Nine trials (90%) were multi-
centre parallel-group trials, one was a multicentre crossover trial (
Quiding 1992). Two trials exclusively included patients with hip
osteoarthritis (Kjaersgaard-Andersen 1990; Quiding 1992), one
trial included only patients with knee osteoarthritis (Zautra 2005),
and six trials included a mixed population of both knee and hip
osteoarthritis (Peloso 2000; Chindalore 2005; Markenson 2005;
Matsumoto 2005; Kivitz 2006; Langford 2006). In six studies
only patients with insufficient analgesic response to paracetamol,
NSAIDs, or previous opioids treatment were included (Caldwell
2002; Chindalore 2005; Kivitz 2006; Langford 2006; Markenson
2005; Matsumoto 2005). The three trials assessing codeine in-
cluded patients with a need for analgesic treatment but without
any requirement of previous insufficient treatment response
(Kjaersgaard-Andersen 1990; Quiding 1992; Peloso 2000); one
trial did not provide information about eligibility criteria concern-
ing the previous analgesic therapy (Zautra 2005).
The Characteristics of excluded studies table displays the reasons
why trials were not considered in this systematic review. Typical
reasons were more than 25% of patients with rheumatoid arthritis
in the sample, the use of active control interventions, or the use
of crossover designs without providing sufficient information on
the first phase.
Risk of bias in included studies
Figure 2 summarises the methodological characteristics and
sources of funding of included trials. Three trials (30%) reported
both adequate sequence generation and adequate allocation con-
cealment (Markenson 2005; Kivitz 2006; Langford 2006); one
trial reported only adequate sequence generation (Matsumoto
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2005); and one trial reported adequate concealment but remained
unclear about the generationof allocation sequence (Zautra 2005).
In the remaining five trials, low quality of reporting hampered
any judgment regarding sequence generation and concealment of
allocation. All 10 trials were described as double blind. Seven tri-
als reported the use of indistinguishable interventions to blind
patients whereas the other three trials used double-dummy tech-
niques (Quiding 1992; Caldwell 2002; Kivitz 2006). However,
only six trials explicitly reported adequate blinding of physicians
(Chindalore 2005; Markenson 2005; Matsumoto 2005; Zautra
2005; Kivitz 2006; Langford 2006). Seven trials described their
analysis to be according to the intention-to-treat principle (Peloso
2000; Chindalore 2005; Markenson 2005; Matsumoto 2005;
Zautra 2005; Kivitz 2006; Langford 2006), but none were con-
sidered to have an intention-to-treat analysis of pain and function
outcomes at end of treatment according to our criteria. Exclusion
of patients from the analysis of pain outcomes ranged from 0.3%
to 52% in the experimental groups and from 2% to 33% in the
control groups. For four trials no information was available on the
proportion of excluded patients (Quiding 1992; Caldwell 2002;
Markenson 2005; Langford 2006). For the analysis of function
outcomes, exclusion of patients ranged from 1% to 48% in the
experimental groups and from 2% to 37% in the control groups;
in two trials no information was available on the proportion of
excluded patients (Caldwell 2002; Markenson 2005).
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Figure 2. Methodological characteristics and source of funding of included trials. (+) indicates low risk of
bias, (?) unclear and (-) a high risk of bias on a specific item.
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Nine trials (90%) reported a primary outcome (Kjaersgaard-
Andersen 1990; Peloso 2000; Caldwell 2002; Chindalore 2005;
Markenson 2005; Matsumoto 2005; Zautra 2005; Kivitz 2006;
Langford 2006) of which five explicitly reported it to be pre-spec-
ified in the protocol (Peloso 2000; Caldwell 2002; Markenson
2005; Matsumoto 2005; Langford 2006) and six trials reported
a sample size calculation for this primary outcome (Kjaersgaard-
Andersen1990; Peloso 2000;Markenson 2005;Matsumoto 2005;
Kivitz 2006; Langford 2006). Eight trials received financial sup-
port froma commercial organisation (Peloso 2000;Caldwell 2002;
Chindalore 2005; Markenson 2005; Matsumoto 2005; Zautra
2005; Kivitz 2006; Langford 2006) whereas no trial was explic-
itly supported by a non-profit organisation. For the effectiveness
outcomes pain and function, the quality of the evidence (Guyatt
2008) was classified as high in view of the low risk of bias in the in-
cluded trials and the lowheterogeneity between trials (Summary of
findings for the main comparison). For adverse event and serious
adverse event outcomes, the quality of the evidence (Guyatt 2008)
was classified as moderate to low because of the small number of
trials reporting the outcomes and the small number of serious ad-
verse events which resulted in imprecise estimates (Summary of
findings for the main comparison).
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
Knee or hip pain
Ten trials including 1541 patients in experimental groups and 727
patients in control groups contributed to the analyses of knee or
hip pain. Figure 3 presents results of the analysis, overall and strat-
ified according to type of opioid. In the overall analysis, combined
oral and transdermal opioids were more effective in pain reduc-
tion than control interventions (SMD -0.36, 95% CI -0.47 to -
0.26), which corresponds to a difference in pain scores of 0.9 cm
on a 10 cm VAS between opioids and placebo. This corresponds
to a difference in improvement of 15% (95% CI 11% to 20%)
between opioids and placebo (Summary of findings for the main
comparison). The estimated difference in the percentage of treat-
ment responders of 4% between opioids and placebo translates
into an NNT to cause one additional treatment response on pain
of 25 (95% CI 19 to 34) (Summary of findings for the main
comparison ). An I2 of 18% indicated a low degree of between-
trial heterogeneity (P for heterogeneity = 0.27). A visual inspection
of the funnel plot suggested slight asymmetry (asymmetry coef-
ficient -1.66, 95% CI -3.74 to 0.43) and the test for asymmetry
indicated limited evidence for asymmetry (P = 0.10) (Figure 4).
Benefits were moderate for codeine (SMD -0.51, 95% CI -1.01
to -0.01; 3 trials), small to moderate for oxycodone (SMD -0.42,
95% CI -0.65 to -0.20; 4 trials) and oxymorphone (SMD -0.39,
95% CI -0.58 to -0.21; 2 trials), and small for morphine (SMD
-0.32, 95% CI -0.59 to -0.06; 1 trial) and transdermal fentanyl
(SMD -0.22, 95% CI -0.42 to -0.03; 1 trial). The confidence in-
tervals were wide and a test for interaction between benefit and
type of opioid was non-significant (P = 0.89). Table 1 presents the
results of stratified analyses. We found little evidence for an asso-
ciation of SMDs with analgesic potency, route of administration,
type of control intervention, treatment duration, use of analgesic
co-interventions, concealment of allocation, or sample size. All
the trials had blinded patients adequately, none had performed
analyses according to the intention-to-treat principle. Therefore,
we could not evaluate the impact of these characteristics. Fourteen
comparisons from 10 trials contributed to the analysis of a lin-
ear association between equivalence dose and treatment benefit (
Figure 5).We found little evidence for a linear association between
daily equivalence doses and pain reduction (P = 0.47).
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Figure 3. Forest plot of 10 trials comparing the effects of any type of opioids and control (placebo or no
intervention) on knee or hip pain. Values on x-axis denote standardised mean differences. The plot is stratified
according to type of opioids. Matsumoto 2005 contributed with two comparisons and the standard error was
inflated and the number of patients in the placebo group was halfed to avoid duplicate counting of patients
when including both comparisons in the overall meta-analysis. Data relating to the 3, 3, 3, and 2 active
intervention arms in Caldwell 2002, Chindalore 2005, Kivitz 2006, and Matsumoto 2005, respectively, were
pooled.
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Figure 4. Funnel plot for effects on knee or hip pain.
Numbers on x-axis refer to standardised mean differences (SMDs), on y-axis to standard errors of SMDs.
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Figure 5. Standardised mean differences of knee or hip pain (y-axis) are plotted against total daily dose of
morphine equivalents (x-axis). The size of the circles is proportional to the random-effects weights that were
used in the meta-regression. The dotted line indicates predicted treatment effects (regression line) from uni-
variable meta-regression by using daily morphine equivalence doses the explanatory variable, and dashed lines
represent the 95% CIs.
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Table 1. Stratified analyses: pain
Variable Number of
studies
N of patients
opioids
N of patients
control
Pain intensity
SMD (95% CI)
Hetero-
geneity
I2 (%)
P-value*
All trials 10 1541 727 -0.36 (-0.47 to -
0.26)
18%
Analgesic
potency
0.74
Weak 3 79 100 -0.51 (-1.01 to -
0.01)
55%
Strong 7 1462 627 -0.38 (-0.49 to -
0.26)
19%
Route of ad-
ministration
0.14
Oral 9 1339 530 -0.42 (-0.54 to -
0.31)
12%
Transdermal 1 202 197 -0.22 (-0.42 to -
0.03)
N/A
Allocation con-
cealment
0.96
Adequate 4 583 384 -0.42 (-0.64 to -
0.20)
56%
Inadequate or
unclear
6 958 343 -0.38 (-0.52 to -
0.25)
3%
Type of control
intervention
0.53
Placebo 8 1493 662 -0.40 (-0.52 to -
0.28)
30%
No interven-
tion
2 48 65 -0.33 (-0.93 to
0.28)
35%
18Oral or transdermal opioids for osteoarthritis of the knee or hip (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Stratified analyses: pain (Continued)
Number
of patients ran-
domised
0.15
> 200 5 1351 527 -0.33 (-0.44 to -
0.23)
0%
≤ 200 5 190 200 -0.55 (-0.83 to -
0.27)
42%
Duration of
treatment
0.23
> 1 month 2 258 248 -0.27 (-0.44 to -
0.09)
0%
≤ 1 month 8 1283 479 -0.43 (-0.56 to -
0.29)
23%
Use of analgesic
co-
interventions
0.66
Similar be-
tween groups
3 289 283 -0.41 (-0.71 to -
0.11)
56%
Unclear 7 1252 444 -0.40 (-0.53 to -
0.28)
14%
*P-value for interaction
Function
Seven studies including 1172 patients in experimental groups and
622 patients in control groups contributed to the analysis of func-
tion. Improvement of function was larger in opioid treated pa-
tients compared to control groups (SMD -0.33, 95% CI -0.45 to
-0.12) (Figure 6), which corresponds to a difference in function
scores of 0.7 units between opioids and placebo on a standard-
ised WOMAC disability scale ranging from 0 to 10. This corre-
sponds to a difference in improvement of 13% (95% CI 9% to
18%) between opioids and placebo (Summary of findings for the
main comparison). The estimated difference in the percentage of
treatment responders between patients allocated to opioids and
patients allocated to placebo of 3% translated into an NNT to
cause one additional treatment response on function of 30 (95%
CI 22 to 46) (Summary of findings for the main comparison ). An
I2 of 24% indicated a low degree of between-trial heterogeneity
(P for heterogeneity = 0.24). We found a moderate benefit for
codeine (SMD -0.42, 95% CI -0.74 to -0.10; 2 trials) and oxy-
codone (SMD -0.44, 95% CI -1.12 to 0.24; 2 trials) and small
effects for oxymorphone (SMD -0.32, 95% CI -0.50 to -0.13; 2
trials), morphine (SMD -0.29, 95% CI -0.56 to -0.03; 1 trial)
and transdermal fentanyl (SMD -0.28, 95% CI -0.48 to -0.09; 1
trial). As was the case for pain, confidence intervals of estimates
were wide and a test for interaction between benefit and type of
opioid was non-significant (P = 0.98). Heterogeneity between the
two trials that studied effects of oxycodone was high with an I2
estimate of 86% (P for heterogeneity < 0.001), but low for the
other types of opioid. The funnel plot (Figure 7) appeared some-
what asymmetrical (asymmetry coefficient -2.49, 95% CI -5.75
to 0.77, P for asymmetry = 0.07). Table 2 presents the results of
the stratified analyses. Again, we found little evidence for an asso-
ciation of SMDs with analgesic potency, route of administration,
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type of control intervention, treatment duration, use of analgesic
co-interventions, and allocation concealment. Adequately pow-
ered trials with more than 200 randomised patients tended to
show smaller improvements of function (P for interaction = 0.09).
Ten comparisons from seven trials contributed to the analysis of a
linear association between equivalence dose and treatment benefit
for function (Figure 8). We found no evidence for an association
between daily equivalence doses and improvement of function (P
= 0.82).
Figure 6. Forest plot of 7 trials comparing the effects of any type of opioids and control (placebo or no
intervention) on function. Values on x-axis denote standardised mean differences. The plot is stratified
according to type of opioids. Matsumoto 2005 contributed with two comparisons and the standard error was
inflated and the number of patients in the placebo group was halved to avoid duplicate counting of patients
when including both comparisons in the overall meta-analysis. Data relating to the 3, 3, and 2 active
intervention arms in Caldwell 2002, Kivitz 2006, and Matsumoto 2005, respectively, were pooled.
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Figure 7. Funnel plot for effects on functioning of the knee or hip.
Numbers on x-axis refer to standardised mean differences (SMDs), on y-axis to standard errors of SMDs
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Figure 8. Standardised mean differences of function (y-axis) are plotted against total daily dose of morphine
equivalents (x-axis). The size of the circles is proportional to the random-effects weights that were used in the
meta-regression. The dotted line indicates predicted treatment effects (regression line) from uni-variable
meta-regression by using daily morphine equivalence doses the explanatory variable, and dashed lines
represent the 95% CIs.
Table 2. Stratified analyses: function
Variable Number of
studies
N of patients
opioids
N of patients
control
Function
SMD (95% CI)
Hetero-
geneity
I2 (%)
P-value*
All trials 7 1172 622 -0.33 (-0.45 to -
0.21)
24%
Analgesic
potency
0.68
22Oral or transdermal opioids for osteoarthritis of the knee or hip (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Stratified analyses: function (Continued)
Weak 2 74 95 -0.42 (-0.74 to -
0.10)
6%
Strong 5 1098 527 -0.35 (-0.48 to -
0.21)
34%
Route of ad-
ministration
0.58
Oral 6 970 425 -0.38 (-0.53 to -
0.23)
28%
Transdermal 1 202 197 -0.28 (-0.48 to -
0.09)
N/A
Allocation con-
cealment
0.60
Adequate 3 528 335 -0.43 (-0.68 to -
0.18)
62%
Inadequate or
unclear
4 644 287 -0.31 (-0.45 to -
0.16)
0%
Type of control
intervention
0.83
Placebo 6 1129 562 -0.36 (-0.50 to -
0.23)
32%
No interven-
tion
1 43 60 -0.29 (-0.68 to
0.11)
N/A
Number
of patients ran-
domised
0.09
> 200 4 1042 476 -0.29 (-0.41 to -
0.18)
0%
≤ 200 3 130 146 -0.56 (-0.88 to -
0.25)
39%
Duration of
treatment
0.55
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Table 2. Stratified analyses: function (Continued)
> 1 month 2 258 248 -0.51 (-1.01 to -
0.01)
81%
≤ 1 month 5 914 374 -0.32 (-0.44 to -
0.19)
0%
Use of analgesic
co-
interventions
0.29
Similar be-
tween groups
3 289 283 -0.53 (-0.88 to -
0.18)
67%
Unclear 4 883 339 -0.30 (-0.43 to -
0.17)
0%
*P-value for interaction
Secondary outcomes
Four trials reported the occurrence of any adverse event in 579 out
of 670 patients in experimental groups and 222 of 410 patients
in control groups (Figure 9). Patients were 55% more likely to
experience adverse events in experimental groups compared to
placebo (RR 1.55, 95% CI 1.41 to 1.70). The NNH to cause one
additional patient to experience an adverse event, as compared to
placebo, was 12 (95% CI 10 to 16) (Summary of findings for
the main comparison ). Results were consistent between different
studies (I2 = 0%, P for heterogeneity = 0.75) and different types
of opioids (P for interaction = 0.95). Due to the low number of
trials, we did not perform an analysis of the association between
equivalence dose and log relative risk for this outcome.
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Figure 9. Forest plot of 4 trials comparing patients experiencing any adverse event between any opioid and
control (placebo or no intervention). Values on x-axis denote risks ratios. The plot is stratified according to
type of opioid. Matsumoto 2005 contributed with two comparisons and the number of patients in the placebo
group was halved to avoid duplicate counting of patients when including both comparisons in the overall meta-
analysis.
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Ten trials with 2403 patients contributed to the meta-analysis of
patients withdrawn or dropped out because of adverse events (
Figure 10). Patients receiving opioid therapy were four times as
likely as patients receiving placebo to be withdrawn or drop out
due to adverse events (RR 4.05, 95% CI 3.06 to 5.38), with little
between trial heterogeneity (I2 = 8%, P for heterogeneity = 0.37).
The NNH to cause one additional dropout or withdrawal due to
adverse events compared with placebo was 19 (95% CI 13 to 29)
(Summary of findings for the main comparison ). We found the
highest pooled risk ratio for oxycodone versus placebo (RR 7.75,
95% CI 3.76 to 15.97) and the lowest pooled RR for transder-
mal fentanyl versus placebo (RR 2.63, 95% CI 1.64 to 4.23) but
confidence intervals were wide and a test for interaction between
type of opioids and relative risk of being withdrawn or dropping
out because of adverse events negative gave a P for interaction of
0.38. Fourteen comparisons in 10 trials contributed to the analysis
of the association between equivalence dose and log relative risk (
Figure 11). We found little evidence for a relationship (P = 0.76).
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Figure 10. Forest plot of 10 trials comparing patients withdrawn or dropped out because of adverse events
between any opioid and control (placebo or no intervention). Values on x-axis denote risks ratios. The plot is
stratified according to type of opioid. Matsumoto 2005 contributed with two comparisons and the number of
patients in the placebo group was halved to avoid duplicate counting of patients when including both
comparisons in the overall meta-analysis. The risk ratio in one trial could not be estimated because no
withdrawals or dropouts because of adverse events occurred in either group.
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Figure 11. Risk ratios of patients withdrawn or dropped out because of adverse events between opioids and
control groups (y-axis) are plotted against total daily dose of morphine equivalents (x-axis). The size of the
circles is proportional to the random-effects weights that were used in the meta-regression. The dotted line
indicates predicted treatment effects (regression line) from uni-variable meta-regression by using daily
morphine equivalence doses the explanatory variable, and dashed lines represent the 95% CIs.
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Three trials with 681 patients contributed to the analysis of pa-
tients experiencing any serious adverse event (Figure 12). Of the
three trials, one trial reported that no patient experienced a seri-
ous adverse event (Kjaersgaard-Andersen 1990). Overall data from
the remaining two trials indicated that patients receiving opioids
tended be more likely to experience a serious adverse event (RR
3.35, 95% CI 0.83 to 13.56). Due to the low number of trials
and events, we neither performed an analysis of the association
between equivalence dose and log relative risk for this outcome,
nor a calculation of NNH to cause one additional patient to expe-
rience a serious adverse event compared with placebo. Only one
trial contributed to the meta-analysis of symptoms of opioid de-
pendency (Langford 2006). The study assessed opiate withdrawal
symptoms after eight weeks of transdermal fentanyl therapy, using
the Short Opiate Withdrawal Scale questionnaire (Gossop 1990;
Langford 2006). Patients in the fentanyl group reported more se-
vere withdrawal symptoms compared with the placebo group with
an SMD of 0.60 (95% CI 0.42 to 0.79), which corresponds to a
mean difference on the Short Opiate Withdrawal Scale of 0.27;
the scale ranges from 0 to 3.
Figure 12. Forest plot of 3 trials comparing patients experiencing any adverse event between any opioid and
control (placebo or no intervention). Values on x-axis denote risks ratios. The plot is stratified according to
type of opioid. The risk ratio in one trial could not be estimated because no serious adverse event occurred in
either group.
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D I S C U S S I O N
Summary of main results
In our systematic review and meta-analysis we found oral or trans-
dermal opioids more effective than placebo in terms of pain relief
and improvement of function in osteoarthritis patients. However,
benefits were only small to moderate. The occurrence of adverse
events often caused patients to stop taking the opioids, which is
likely to limit the usefulness of opioids in the long term. The po-
tentially higher risk of serious adverse events and substance ad-
diction might further limit their use. The reporting of safety out-
comes was incomplete and adverse events were reported in four
trials, and serious adverse events in three trials only.
Quality of the evidence
Most of the trials were funded by the pharmaceutical industry
and we did not have enough data to explore whether the type
of funding was associated with the estimated treatment effects.
The effectiveness of opioids may drop after chronic use as the
effects of opioids are mediated through opioids receptors. Our
analysis of this characteristic was hampered by the low number of
studies (two only) reporting opioid use for more than four weeks.
The relatively low dose of morphine equivalents (median daily
dose 51 mg) administered in the included trials might provide an
explanation of the small benefits observed as compared with other
studies (Maier 2002 ). Our ability to provide a reliable assessment
of dose dependency might have been hampered by the generally
low morphine equivalent doses used and the lack of individual
participant data.
Data on risks of addiction due to opioids therapy is scarce, and
currently available trials are not designed to evaluate these issues.
There is a clear need for additional randomised trials and obser-
vational studies using longer follow-up times to address the risks
of substance dependence associated with different opioids. In this
systematic review only one trial reported measures of the severity
of withdrawal symptoms (Langford 2006). Similar to previous sys-
tematic reviews of randomised trials on opioids therapy for non-
cancer pain (Kalso 2004; Furlan 2006), we found that most of the
trials included in our review had a treatment duration of several
days or a few weeks only. This is too short to address the impact
of opioid treatment on routine clinical practice in the treatment
of a chronic condition like osteoarthritis. While no evidence of
long-term effects is available from randomised trials, observational
studies indicate that long-term treatment with opioids of chronic
conditions such as osteoarthritis may have deleterious effects and
do not seem to improve pain relief (Eriksen 2006).
Potential biases in the review process
We based our review on a broad literature search. Even though
we cannot exclude potential publication bias, it seems rather un-
likely that we missed relevant trials (Egger 2003). Selection of
trials and data extraction were performed independently by two
review authors to minimise bias and transcription errors (Egger
2001; Gøtzsche 2007). The most recent systematic review on opi-
oids for osteoarthritis (Avouac 2007), updated in October 2006,
considered 18 studies that compared opioids to placebo. We in-
cluded data from six of these in our meta-analysis and data from
four additional trials (Kjaersgaard-Andersen 1990; Quiding 1992;
Matsumoto 2005; Kivitz 2006). We excluded six trials with tra-
madol as the experimental intervention and one trial that was
likely to have included only a minority of osteoarthritis patients.
In conclusion, we are likely to have included all relevant trials in
our systematic review.
Agreements and disagreements with other
studies or reviews
We excluded tramadol from our review to avoid overlap with an-
other Cochrane Review that focused on this specific opioid in
osteoarthritis (Cepeda 2006). Extracted pain and function out-
comes and follow-up time in the previous systematic review about
opioids for osteoarthritis (Avouac 2007) were similar to our sys-
tematic review. Comparing opioids with placebo controls, Avouac
2007 found a large pooled effects for pain intensity (SMD -0.79,
95% CI -0.98 to -0.59) and a moderate pooled effect for function
(SMD -0.31, 95% CI -0.39 to -0.24). These effects are consis-
tent with our results for function but are substantially larger for
pain reduction. This discrepancy might be due to the exclusion of
some trials in our systematic review. Avouac 2007 reported mod-
erate to large effects of tramadol for pain, between -0.36 to -0.93
standard deviation units, in several large trials and unrealistically
large beneficial effects on pain intensity in an oxycodone trial that
was excluded from our review (Roth 2000). These trials often did
not report function outcomes and could not, therefore, contribute
to the pooled analysis, or they reported considerably smaller ef-
fects for function than for pain (Avouac 2007). In line with other
studies, we found that adverse events occurring in patients treated
with opioids often caused withdrawals and dropouts (Kalso 2004;
Furlan 2006; Avouac 2007 ). Tramadol may be similar to or even
more effective than the opioids evaluated in our review, in reduc-
ing pain and improving function, but safety concerns have to be
addressed further (Cepeda 2006).
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Implications for practice
Opioids decrease pain intensity and improve function but the ben-
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efits observed are small to moderate and increases in doses do not
appear to result in further pain reduction. The occurrence of ad-
verse events often caused patients to stop taking the preparations,
which is likely to limit their usefulness in the long-term treatment
of osteoarthritis of the hip or knee. The higher risk of serious ad-
verse events and the potential occurrence of addiction to opioid
therapy might further limit their clinical use. Taken together, our
results indicate that the small tomoderate beneficial effects of non-
tramadol opioids are outweighed by large increases in the risk of
adverse events. Even in patients with severe osteoarthritic pain,
clinicians are advised to use non-tramadol opioids cautiously and
to consider alternatives, such as surgery. In addition, clinicians
should inform patients about the substantial risks and only mod-
erate benefits of opioid treatment and therapeutic alternatives.
Implications for research
The effectiveness and safety of opioid and non-opioid analgesics
should be directly compared in appropriately powered randomised
controlled trials accompanied by network meta-analyses, which
integrate direct and indirect evidence in one single analysis while
maintaining randomisation (Caldwell 2005). Efficacy and safety
data on transdermal opioids are scarce (one trial) suggesting the
need for further trials using transdermal preparations. Further tri-
als might be required to better evaluate the effects of the route of
administration, the difference between weak and strong opioids,
and dose effects. The evidence of the effectiveness and safety of
opioid therapy is mainly from a few short-term trials, despite the
fact that the underlying condition is chronic and requires safe,
long-term treatments (Kalso 2004; Furlan 2006). Further long-
term randomised trials or observational studies are needed to in-
crease our understanding of their long-term effectiveness, safety,
and the potential for addiction.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Caldwell 2002
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 4 weeks
Multicentre trial
No power calculation reported
Participants Patients with prior suboptimal analgesic response to NSAIDs/paracetamol or previous
intermittent opioid therapy were eligible
295 patients with knee and/or hip osteoarthritis were reported at baseline
Number of females: 184 of 295 (62%)
Average age: 62 years
Interventions Experimental interventions
a) oral morphine (Avinza), 30mg once daily in the morning
b) oral morphine (Avinza), 30mg once daily in the evening
c) oral morphine sulphate (Contin), 15mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 4 weeks
No analgesics other than study drugs allowed
Outcomes Extracted pain outcome: global pain after 4 weeks
Extracted function outcome: WOMAC disability subscore after 4 weeks
Primary outcome: WOMAC OA index
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
Allocation concealment? Unclear No information provided.
Described as double-blind? Yes
Blinding of patients? Yes
Blinding of physicians? Unclear No information provided.
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Caldwell 2002 (Continued)
Blinding of outcome assessors? Yes
Interventions reported as indistinguish-
able?
No
Double-dummy technique used? Yes
Intention-to-treat analysis performed?
Pain
No No information on exclusions available.
Intention-to-treat analysis performed?
Function
No No information on exclusions available.
No funding by commercial organisation? No Sponsor: Elan
Chindalore 2005
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 4 weeks
Randomisation stratified according to gender
Multicentre trial with 37 centres
No power calculation reported
Participants Patients with moderate to severe hip or knee pain while taking ≥1 oral analgesic medi-
cation were eligible
362 patients were randomised
360 patients with hip or knee osteoarthritis were reported at baseline
Number of females: 249 of 360 (69%)
Average age: 54 years
Interventions Experimental interventions
a) oral oxycodone, 10mg 4-times daily
b) oral oxycodone, 2.5 mg 4-times daily, plus naltrexone, 0.001 mg 4-times daily
(Oxytrex)
c) oral oxycodone, 2.5 mg 4-times daily, plus natronex, 0.001 mg twice daily (Oxytrex)
Control intervention
Placebo, twice daily
Treatment duration: 3 weeks
Analgesics other than study drugs allowed, but it was unclear whether intake was similar
between groups
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Chindalore 2005 (Continued)
Outcomes Extracted pain outcome: global pain after 4 weeks
Extracted function outcome: WOMAC disability subscore after 4 weeks
Primary outcome: pain intensity during the past 24 hours
Notes For WOMAC disability, insufficient data were reported to calculate standardised mean
differences and it was therefore not included in the meta-analysis
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
Allocation concealment? Unclear No information provided.
Described as double-blind? Yes
Blinding of patients? Yes
Blinding of physicians? Yes
Blinding of outcome assessors? Yes
Interventions reported as indistinguish-
able?
Yes
Double-dummy technique used? No
Intention-to-treat analysis performed?
Pain
No 1 of 310 patients (0.3%) excluded in experimental groups, 1 of
52 patients (1.9%) excluded in control group.
Intention-to-treat analysis performed?
Function
No 1 of 310 patients (0.3%) excluded in experimental groups, 1 of
52 (1.9%) patients excluded in control group.
No funding by commercial organisation? No Sponsor: Pain Therapeutics
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Kivitz 2006
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 2 weeks
Multicentre trial
Power calculation reported
Participants Patients with suboptimal analgesic response to NSAIDs/paracetamol or previous opioid
therapy were eligible
370 patients were randomised
370 patients with knee or hip osteoarthritis were reported at baseline
Affected joints: 297 knees and 73 hips
Number of females: 224 of 370 (61%)
Interventions Experimental interventions
a) oral extended-release oxymorphone, 10mg twice daily
b) oral extended-release oxymorphone, 40mg twice daily
c) oral extended-release oxymorphone, 50mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 2 weeks
No analgesics other than study drugs allowed.
Outcomes Extracted pain outcome: global pain after 2 weeks.
Extracted function outcome: WOMAC disability subscore after 2 weeks
Primary outcome: change in pain intensity
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes
Allocation concealment? Yes
Described as double-blind? Yes
Blinding of patients? Yes
Blinding of physicians? Yes
Blinding of outcome assessors? Yes
Interventions reported as indistinguish-
able?
No
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Kivitz 2006 (Continued)
Double-dummy technique used? Yes
Intention-to-treat analysis performed?
Pain
No 9 of 279 patients (0.7%) excluded in experimental groups, 4 of
91 patients (4.4%) excluded in control group.
Intention-to-treat analysis performed?
Function
No 9 of 279 patients (0.7%) excluded in experimental groups, 4 of
91 patients (4.4%) excluded in control group.
No funding by commercial organisation? No Sponsor: Endo Pharmaceuticals Inc, Penwest Pharmaceuticals
Co.
Kjaersgaard-Andersen 1990
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 4 weeks
Multicentre trial with 7 centres
Power calculation reported
Participants Patients with chronic pain requiring analgesic treatment were eligible
158 patients with hip osteoarthritis were reported at baseline
Affected joints: 158 hips
Number of females: 72 of 158 (46%)
Average age: 66 years
Average BMI: 26 kg/m2
Interventions Experimental intervention
Oral codeine 60 mg plus paracetamol 1000 mg, 3 times daily
Control intervention
Paracetamol 1000 mg, 3 times daily
Treatment duration: 4 weeks
No analgesics other than study drugs allowed
Outcomes Extracted pain outcome: global pain after 4 weeks
Extracted function outcome: patient’s global assessment after 4 weeks
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
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Kjaersgaard-Andersen 1990 (Continued)
Allocation concealment? Unclear No information provided.
Described as double-blind? Yes
Blinding of patients? Yes
Blinding of physicians? Unclear No information provided.
Blinding of outcome assessors? Yes
Interventions reported as indistinguish-
able?
Yes
Double-dummy technique used? No
Intention-to-treat analysis performed?
Pain
No 43 of 83 patients (52%) excluded in experimental group, 18 of
75 patients (24%) excluded in control group.
Intention-to-treat analysis performed?
Function
No 40 of 83 patients (48%) excluded in experimental group, 15 of
75 patients (20%) excluded in control group.
No funding by commercial organisation? Unclear No information provided.
Langford 2006
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 8 weeks
Randomisation stratified according to target joint (knee/hip)
Multicentre trial
Power calculation reported
Participants Patients without adequate pain control under weak opioid treatment (with and without
paracetamol) were eligible
416 patients were randomised
399 patients with knee or hip osteoarthritis were reported at baseline
Affected joints: 211 knees and 188 hips
Number of females: 265 of 399 (66%)
Interventions Experimental intervention
Transdermal fentanyl (Durogesic), median dosage 25µg/hour
Control intervention
Placebo
Treatment duration: 6 weeks
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Langford 2006 (Continued)
Analgesics other than study drugs allowed and intake assessed, but unclear whether intake
was similar between groups
Outcomes Extracted pain outcome: global pain after 8 weeks
Extracted function outcome: WOMAC disability subscore after 8 weeks
Primary outcome: pain relief on VAS
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes
Allocation concealment? Yes
Described as double-blind? Yes
Blinding of patients? Yes
Blinding of physicians? Yes
Blinding of outcome assessors? Unclear No information provided.
Interventions reported as indistinguish-
able?
Yes
Double-dummy technique used? No
Intention-to-treat analysis performed?
Pain
No No information on exclusions available.
Intention-to-treat analysis performed?
Function
No No information on exclusions available.
No funding by commercial organisation? No Sponsor: Janssen-Cilag
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Markenson 2005
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 13 weeks
Multicentre trial with 9 centres
Power calculation reported
Participants Patients with moderate to severe pain while taking NSAIDs/paracetamol, with con-
traindications to NSAID therapy or with previous oral opioid therapy were eligible
109 patients were randomised
107 patients with osteoarthritis were reported at baseline
Affected joints: 33 knees, 19 hips, and 57 other joints
Number of females: 78 of 107 (73%)
Average age: 63 years
Interventions Experimental intervention
Oral oxycodone (OxyContin), 10mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 13 weeks
Analgesics other than study drugs allowed and intake assessed, but unclear whether intake
was similar
Outcomes Extracted pain outcome: global pain after 13 weeks
Extracted function outcome: WOMAC global scale after 13 weeks
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes
Allocation concealment? Yes
Described as double-blind? Yes
Blinding of patients? Yes
Blinding of physicians? Yes
Blinding of outcome assessors? Yes
Interventions reported as indistinguish-
able?
Yes
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Markenson 2005 (Continued)
Double-dummy technique used? No
Intention-to-treat analysis performed?
Pain
No No information on exclusions available.
Intention-to-treat analysis performed?
Function
No No information on exclusions available.
No funding by commercial organisation? No Sponsor: Purdue Pharma
Matsumoto 2005
Methods Randomised controlled trial
4-arm parallel group design
Trial duration: 4 weeks
Simple randomisation
Multicentre trial
Power calculation reported
Participants Patients with suboptimal analgesic response to NSAIDs, paracetamol, or opioids were
eligible
491 patients were randomised
489 patients with OA were reported at baseline
Affected joints: 373 knees and 116 hips
Number of females: 297 of 489 (61%)
Average age: 62 years
Average BMI: 34 kg/m2
Interventions Experimental interventions
a) Oral extended-release oxymorphone, 20mg twice daily
b) Oral extended-release oxymorphone, 40mg twice daily
c) Oral controlled-release oxycodone, 20mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 4 weeks
No analgesics other than study drugs allowed
Outcomes Extracted pain outcome: WOMAC pain subscore after 4 weeks
Extracted function outcome: WOMAC disability subscore after 4 weeks
Primary outcome: change in arthritis pain intensity
Notes
Risk of bias
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Matsumoto 2005 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes
Allocation concealment? Unclear No information provided.
Described as double-blind? Yes
Blinding of patients? Yes
Blinding of physicians? Yes
Blinding of outcome assessors? Yes
Interventions reported as indistinguish-
able?
Yes
Double-dummy technique used? No
Intention-to-treat analysis performed?
Pain
No 19 of 367 patients (5.2%) excluded in experimental groups, 5
of 124 (4.0%) patients excluded in control group.
Intention-to-treat analysis performed?
Function
No 19 of 367 patients (5.2%) excluded in experimental groups, 5
of 124 (4.0%) patients excluded in control group.
No funding by commercial organisation? No Sponsors: TheraQuest Biosciences, Endo Pharmaceuticals, Pen-
west Pharmaceuticals Co.
Peloso 2000
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 4 weeks
Multicentre trial with 4 centres
Power calculation reported
Participants Patients with osteoarthritis symptoms requiring therapy with paracetamol, anti-inflam-
matory agents or opioids were eligible.
103 patients were randomised
103 patients with osteoarthritis were reported at baseline
Affected joints: 94 knees and 49 hips
Number of females: 64 of 103 (62%)
Average age: 62 years
Average BMI: 34 kg/m2
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Peloso 2000 (Continued)
Average disease duration: 10.3 years
Interventions Experimental intervention
Oral codeine (Contin), 100mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 4 weeks
Analgesics other than study drugs allowed and intake assessed, but unclear whether intake
was similar between groups
Outcomes Extracted pain outcome: global pain after 4 weeks
Extracted function outcome: WOMAC disability subscore after 4 weeks
Primary outcome: WOMAC pain and overall pain intensity
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
Allocation concealment? Unclear No information provided.
Described as double-blind? Yes
Blinding of patients? Yes
Blinding of physicians? Unclear No information provided.
Blinding of outcome assessors? Unclear No information provided.
Interventions reported as indistinguish-
able?
Yes
Double-dummy technique used? No
Intention-to-treat analysis performed?
Pain
No 20 of 51 patients (39%) excluded in experimental group, 17 of
52 patients (33%) excluded in control group.
Intention-to-treat analysis performed?
Function
No 20 of 51 patients (39%) excluded in experimental group, 17 of
52 patients (33%) excluded in control group.
No funding by commercial organisation? No Sponsor: Purdue Frederick
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Quiding 1992
Methods Randomised controlled trial
3-arm crossover design
Trial duration: 1 week
No power calculation reported
Participants Patients in need of analgesic medication for hip osteoarthritis were eligible
27 patients were randomised
26 patients with OA were reported at baseline
Affected joints: 26 hips
Number of females: 22 of 26 (85%)
Average age: 53 years
Interventions Experimental intervention
30 mg oral codeine plus 200 mg ibuprofen, 6 times in 32 hours
Control intervention
200 mg ibuprofen, 6 times in 32 hours
Treatment duration: 32 hours
No analgesics other than study drugs allowed
Outcomes Extracted pain outcome: global pain after 1 week
No function outcome reported
No primary outcome reported
Notes 1 trial arm excluded from review
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
Allocation concealment? Unclear No information provided.
Described as double-blind? Yes
Blinding of patients? Yes
Blinding of physicians? Unclear No information provided.
Blinding of outcome assessors? Yes
Interventions reported as indistinguish-
able?
No
Double-dummy technique used? Yes
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Quiding 1992 (Continued)
Intention-to-treat analysis performed?
Pain
Unclear No information on exclusions available.
Intention-to-treat analysis performed?
Function
Unclear Not applicable, no function outcome reported.
No funding by commercial organisation? Unclear No information provided.
Zautra 2005
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 13 weeks
Multicentre trial with 9 centres
No power calculation reported
Participants 107 patients were randomised
104 patients with knee osteoarthritis were reported at baseline
Number of females: 76 of 104 (73%)
Average age: 63 years
Interventions Experimental intervention
Oral oxycodone (Oxycontin), 10mg twice daily
Control intervention
Placebo, twice daily
Treatment duration: 13 weeks
Analgesics other than study drugs allowed, but it was unclear whether intake was similar
between groups
Outcomes Extracted pain outcome: global pain after 13 weeks
No function outcome reported
Primary outcome: coping efficacy and arthritis helplessness
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
Allocation concealment? Yes
Described as double-blind? Yes
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Zautra 2005 (Continued)
Blinding of patients? Yes
Blinding of physicians? Yes
Blinding of outcome assessors? Yes
Interventions reported as indistinguish-
able?
Yes
Double-dummy technique used? No
Intention-to-treat analysis performed?
Pain
No 1 of 56 patients (1.8%) excluded in experimental group, 2 of 51
patients (3.9%) excluded in control group.
Intention-to-treat analysis performed?
Function
Unclear Not applicable, no function outcome reported.
No funding by commercial organisation? No Sponsor: Purdue Pharma
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Characteristics of excluded studies [ordered by study ID]
Adams 2006 Only active control interventions.
Andrei 1984 Percentage of patients with knee or hip osteoarthritis 17% (5/30).
Boureau 1990 Only active control interventions.
Brooks 1982 Percentage of patients with osteoarthritis 50%, no information about joints involved.
Burch 2004 No randomised controlled trial.
Caldwell 1999 Percentage of patients with knee or hip osteoarthritis likely to be below 50%.
Choquette 2008 No randomised controlled trial.
Doak 1992 Crossover trial providing pooled results only.
Fancourt 1984 Mixed population of rheumatoid arthritis and osteoarthritis, no information about number of patients with
osteoarthritis.
Gazi 2005 Only active control interventions.
Hale 2007 Only active control interventions.
Le Loet 2005 Not randomised controlled trial.
McIlwain 2005 Not randomised controlled trial.
Mitchell 1984 Mixed population of rheumatoid arthritis and osteoarthritis, no information about number of patients with
osteoarthritis.
Neubauer 1983 Percentage of patients with osteoarthritis 15% (5/33).
Rosenthal 2007 Not randomised controlled trial.
Roth 2000 Percentage of patients with knee or hip osteoarthritis likely to be below 50%.
Salzman 1983 Only active control interventions.
Tassain 2003 Percentage of patients with osteoarthritis 7% (2/28).
Torres 2001 Not randomised controlled trial.
Vignon 1999 Comparison of combination of dextropropoxyphene, acetaminophen, and caffeine with placebo.
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(Continued)
Vlok 1987 Crossover trial providing pooled results only.
Wallace 1994 Crossover trial providing pooled results only.
Wang 1965 Percentage of patients with osteoarthritis 6% (2/34).
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Characteristics of studies awaiting assessment [ordered by study ID]
Kroner 1991
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 3 weeks
Multicentre trial
Participants 131 patients with hip osteoarthritis were reported at baseline
Number of females: 70 of 131 (53%)
Interventions Experimental intervention
Codeine 30mg plus paracetamol 500mg
Control intervention
Paracetamol 500mg
Treatment duration: 3 weeks
Outcomes Assessed efficacy outcomes: pain intensity, pain relief, patient’s evaluation of the effect of treatment
Assessed safety outcomes: number of patients withdrawn due to adverse events, serious adverse events
Notes Insufficient data provided in published abstract, no full-text article available. Awaiting author response.
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D A T A A N D A N A L Y S E S
Comparison 1. Opioids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 10 2268 Std. Mean Difference (Random, 95% CI) -0.36 [-0.47, -0.26]
1.1 Codeine 3 179 Std. Mean Difference (Random, 95% CI) -0.51 [-1.01, -0.01]
1.2 Fentanyl 1 399 Std. Mean Difference (Random, 95% CI) -0.22 [-0.42, -0.03]
1.3 Morphine 1 295 Std. Mean Difference (Random, 95% CI) -0.32 [-0.59, -0.06]
1.4 Oxycodone 4 750 Std. Mean Difference (Random, 95% CI) -0.42 [-0.65, -0.20]
1.5 Oxymorphone 2 645 Std. Mean Difference (Random, 95% CI) -0.39 [-0.58, -0.21]
2 Function 7 1794 Std. Mean Difference (Random, 95% CI) -0.33 [-0.45, -0.21]
2.1 Codeine 2 169 Std. Mean Difference (Random, 95% CI) -0.42 [-0.74, -0.10]
2.2 Fentanyl 1 399 Std. Mean Difference (Random, 95% CI) -0.28 [-0.48, -0.09]
2.3 Morphine 1 295 Std. Mean Difference (Random, 95% CI) -0.29 [-0.56, -0.03]
2.4 Oxycodone 2 286 Std. Mean Difference (Random, 95% CI) -0.44 [-1.12, 0.24]
2.5 Oxymorphone 2 645 Std. Mean Difference (Random, 95% CI) -0.32 [-0.50, -0.13]
3 Number of patients experiencing
any adverse event
4 1080 Risk Ratio (IV, Random, 95% CI) 1.55 [1.41, 1.70]
3.1 Codeine 1 66 Risk Ratio (IV, Random, 95% CI) 1.28 [0.94, 1.75]
3.2 Fentanyl 1 416 Risk Ratio (IV, Random, 95% CI) 1.55 [1.33, 1.81]
3.3 Oxycodone 2 294 Risk Ratio (IV, Random, 95% CI) 1.62 [1.36, 1.92]
3.4 Oxymorphone 1 304 Risk Ratio (IV, Random, 95% CI) 1.59 [1.28, 1.97]
4 Number of patients who
withdrew because of adverse
events
10 2403 Risk Ratio (IV, Random, 95% CI) 4.05 [3.06, 5.38]
4.1 Codeine 3 277 Risk Ratio (IV, Random, 95% CI) 3.67 [2.16, 6.24]
4.2 Fentanyl 1 399 Risk Ratio (IV, Random, 95% CI) 2.63 [1.64, 4.23]
4.3 Morphine 1 295 Risk Ratio (IV, Random, 95% CI) 3.49 [1.45, 8.39]
4.4 Oxycodone 4 758 Risk Ratio (IV, Random, 95% CI) 7.75 [3.76, 15.97]
4.5 Oxymorphone 2 674 Risk Ratio (IV, Random, 95% CI) 5.32 [2.93, 9.68]
5 Number of patients experiencing
any serious adverse event
3 681 Risk Ratio (IV, Random, 95% CI) 3.35 [0.83, 13.56]
5.1 Codeine 1 158 Risk Ratio (IV, Random, 95% CI) Not estimable
5.2 Fentanyl 1 416 Risk Ratio (IV, Random, 95% CI) 2.78 [0.57, 13.60]
5.3 Oxycodone 1 107 Risk Ratio (IV, Random, 95% CI) 6.39 [0.34, 120.71]
6 Withdrawal symptoms 1 499 Std. Mean Difference (IV, Fixed, 95% CI) 0.60 [0.42, 0.79]
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Analysis 1.1. Comparison 1 Opioids versus placebo, Outcome 1 Pain.
Review: Oral or transdermal opioids for osteoarthritis of the knee or hip
Comparison: 1 Opioids versus placebo
Outcome: 1 Pain
Study or subgroup Experimental Control Std. Mean Difference (SE) Std. Mean Difference Weight Std. Mean Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Codeine
Kjaersgaard-Andersen 1990 40 57 -0.143 (0.207) 6.1 % -0.14 [ -0.55, 0.26 ]
Quiding 1992 8 8 -0.844 (0.525) 1.1 % -0.84 [ -1.87, 0.18 ]
Peloso 2000 31 35 -0.783 (0.256) 4.2 % -0.78 [ -1.28, -0.28 ]
Subtotal (95% CI) 11.3 % -0.51 [ -1.01, -0.01 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 4.44, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 2.00 (P = 0.046)
2 Fentanyl
Langford 2006 202 197 -0.223 (0.1) 18.8 % -0.22 [ -0.42, -0.03 ]
Subtotal (95% CI) 18.8 % -0.22 [ -0.42, -0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.026)
3 Morphine
Caldwell 2002 222 73 -0.322 (0.136) 12.2 % -0.32 [ -0.59, -0.06 ]
Subtotal (95% CI) 12.2 % -0.32 [ -0.59, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
4 Oxycodone
Zautra 2005 55 49 -0.807 (0.204) 6.3 % -0.81 [ -1.21, -0.41 ]
Matsumoto 2005 120 59 -0.247 (0.159) 9.6 % -0.25 [ -0.56, 0.06 ]
Chindalore 2005 309 51 -0.316 (0.152) 10.3 % -0.32 [ -0.61, -0.02 ]
Markenson 2005 56 51 -0.431 (0.196) 6.7 % -0.43 [ -0.82, -0.05 ]
Subtotal (95% CI) 32.8 % -0.42 [ -0.65, -0.20 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 5.23, df = 3 (P = 0.16); I2 =43%
Test for overall effect: Z = 3.66 (P = 0.00025)
5 Oxymorphone
Matsumoto 2005 228 60 -0.395 (0.147) 10.8 % -0.40 [ -0.68, -0.11 ]
Kivitz 2006 270 87 -0.391 (0.124) 14.0 % -0.39 [ -0.63, -0.15 ]
Subtotal (95% CI) 24.8 % -0.39 [ -0.58, -0.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 4.14 (P = 0.000034)
Total (95% CI) 100.0 % -0.36 [ -0.47, -0.26 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 12.26, df = 10 (P = 0.27); I2 =18%
Test for overall effect: Z = 6.68 (P < 0.00001)
-2 -1 0 1 2
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Analysis 1.2. Comparison 1 Opioids versus placebo, Outcome 2 Function.
Review: Oral or transdermal opioids for osteoarthritis of the knee or hip
Comparison: 1 Opioids versus placebo
Outcome: 2 Function
Study or subgroup Experimental Control Std. Mean Difference (SE) Std. Mean Difference Weight Std. Mean Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Codeine
Kjaersgaard-Andersen 1990 43 60 -0.288 (0.201) 8.0 % -0.29 [ -0.68, 0.11 ]
Peloso 2000 31 35 -0.621 (0.253) 5.3 % -0.62 [ -1.12, -0.13 ]
Subtotal (95% CI) 13.3 % -0.42 [ -0.74, -0.10 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.06, df = 1 (P = 0.30); I2 =6%
Test for overall effect: Z = 2.58 (P = 0.010)
2 Fentanyl
Langford 2006 202 197 -0.283 (0.101) 21.8 % -0.28 [ -0.48, -0.09 ]
Subtotal (95% CI) 21.8 % -0.28 [ -0.48, -0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0051)
3 Morphine
Caldwell 2002 222 73 -0.291 (0.135) 15.0 % -0.29 [ -0.56, -0.03 ]
Subtotal (95% CI) 15.0 % -0.29 [ -0.56, -0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
4 Oxycodone
Matsumoto 2005 120 59 -0.107 (0.159) 11.7 % -0.11 [ -0.42, 0.20 ]
Markenson 2005 56 51 -0.798 (0.201) 8.0 % -0.80 [ -1.19, -0.40 ]
Subtotal (95% CI) 19.7 % -0.44 [ -1.12, 0.24 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 7.27, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.28 (P = 0.20)
5 Oxymorphone
Matsumoto 2005 228 60 -0.273 (0.146) 13.3 % -0.27 [ -0.56, 0.01 ]
Kivitz 2006 270 87 -0.353 (0.124) 16.8 % -0.35 [ -0.60, -0.11 ]
Subtotal (95% CI) 30.2 % -0.32 [ -0.50, -0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 3.38 (P = 0.00072)
Total (95% CI) 100.0 % -0.33 [ -0.45, -0.21 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 9.23, df = 7 (P = 0.24); I2 =24%
Test for overall effect: Z = 5.41 (P < 0.00001)
-1 -0.5 0 0.5 1
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Analysis 1.3. Comparison 1 Opioids versus placebo, Outcome 3 Number of patients experiencing any
adverse event.
Review: Oral or transdermal opioids for osteoarthritis of the knee or hip
Comparison: 1 Opioids versus placebo
Outcome: 3 Number of patients experiencing any adverse event
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Codeine
Peloso 2000 25/31 22/35 9.7 % 1.28 [ 0.94, 1.75 ]
Subtotal (95% CI) 31 35 9.7 % 1.28 [ 0.94, 1.75 ]
Total events: 25 (Experimental), 22 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
2 Fentanyl
Langford 2006 169/216 101/200 38.8 % 1.55 [ 1.33, 1.81 ]
Subtotal (95% CI) 216 200 38.8 % 1.55 [ 1.33, 1.81 ]
Total events: 169 (Experimental), 101 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 5.57 (P < 0.00001)
3 Oxycodone
Matsumoto 2005 110/125 35/62 17.7 % 1.56 [ 1.24, 1.96 ]
Markenson 2005 52/56 28/51 13.7 % 1.69 [ 1.31, 2.19 ]
Subtotal (95% CI) 181 113 31.5 % 1.62 [ 1.36, 1.92 ]
Total events: 162 (Experimental), 63 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 5.49 (P < 0.00001)
4 Oxymorphone
Matsumoto 2005 223/242 36/62 20.0 % 1.59 [ 1.28, 1.97 ]
Subtotal (95% CI) 242 62 20.0 % 1.59 [ 1.28, 1.97 ]
Total events: 223 (Experimental), 36 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.22 (P = 0.000025)
Total (95% CI) 670 410 100.0 % 1.55 [ 1.41, 1.70 ]
Total events: 579 (Experimental), 222 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.94, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 8.93 (P < 0.00001)
0.5 0.7 1 1.5 2
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Analysis 1.4. Comparison 1 Opioids versus placebo, Outcome 4 Number of patients who withdrew because
of adverse events.
Review: Oral or transdermal opioids for osteoarthritis of the knee or hip
Comparison: 1 Opioids versus placebo
Outcome: 4 Number of patients who withdrew because of adverse events
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Codeine
Kjaersgaard-Andersen 1990 40/83 10/75 3.61 [ 1.95, 6.71 ]
Peloso 2000 15/51 4/52 3.82 [ 1.36, 10.74 ]
Quiding 1992 0/8 0/8 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 142 135 3.67 [ 2.16, 6.24 ]
Total events: 55 (Experimental), 14 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 4.80 (P < 0.00001)
2 Fentanyl
Langford 2006 54/202 20/197 2.63 [ 1.64, 4.23 ]
Subtotal (95% CI) 202 197 2.63 [ 1.64, 4.23 ]
Total events: 54 (Experimental), 20 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.00 (P = 0.000062)
3 Morphine
Caldwell 2002 53/222 5/73 3.49 [ 1.45, 8.39 ]
Subtotal (95% CI) 222 73 3.49 [ 1.45, 8.39 ]
Total events: 53 (Experimental), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0053)
4 Oxycodone
Chindalore 2005 79/309 0/51 26.67 [ 1.68, 423.49 ]
Markenson 2005 20/56 2/51 9.11 [ 2.24, 37.05 ]
Matsumoto 2005 31/125 3/62 5.13 [ 1.63, 16.11 ]
Zautra 2005 20/55 2/49 8.91 [ 2.19, 36.19 ]
Subtotal (95% CI) 545 213 7.75 [ 3.76, 15.97 ]
Total events: 150 (Experimental), 7 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.36, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 5.55 (P < 0.00001)
5 Oxymorphone
Kivitz 2006 122/279 9/91 4.42 [ 2.34, 8.34 ]
0.02 0.1 1 10 50
Favours experimental Favours control
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Matsumoto 2005 103/242 3/62 8.80 [ 2.89, 26.79 ]
Subtotal (95% CI) 521 153 5.32 [ 2.93, 9.68 ]
Total events: 225 (Experimental), 12 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.11, df = 1 (P = 0.29); I2 =10%
Test for overall effect: Z = 5.48 (P < 0.00001)
Total (95% CI) 1632 771 4.05 [ 3.06, 5.38 ]
Total events: 537 (Experimental), 58 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 9.77, df = 9 (P = 0.37); I2 =8%
Test for overall effect: Z = 9.71 (P < 0.00001)
0.02 0.1 1 10 50
Favours experimental Favours control
Analysis 1.5. Comparison 1 Opioids versus placebo, Outcome 5 Number of patients experiencing any
serious adverse event.
Review: Oral or transdermal opioids for osteoarthritis of the knee or hip
Comparison: 1 Opioids versus placebo
Outcome: 5 Number of patients experiencing any serious adverse event
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Codeine
Kjaersgaard-Andersen 1990 0/83 0/75 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 83 75 0.0 [ 0.0, 0.0 ]
Total events: 0 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 Fentanyl
Langford 2006 6/216 2/200 2.78 [ 0.57, 13.60 ]
Subtotal (95% CI) 216 200 2.78 [ 0.57, 13.60 ]
Total events: 6 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
3 Oxycodone
Markenson 2005 3/56 0/51 6.39 [ 0.34, 120.71 ]
Subtotal (95% CI) 56 51 6.39 [ 0.34, 120.71 ]
0.005 0.1 1 10 200
Favours experimental Favours control
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Total events: 3 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
Total (95% CI) 355 326 3.35 [ 0.83, 13.56 ]
Total events: 9 (Experimental), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.090)
0.005 0.1 1 10 200
Favours experimental Favours control
Analysis 1.6. Comparison 1 Opioids versus placebo, Outcome 6 Withdrawal symptoms.
Review: Oral or transdermal opioids for osteoarthritis of the knee or hip
Comparison: 1 Opioids versus placebo
Outcome: 6 Withdrawal symptoms
Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Langford 2006 202 0.66 (0.57) 297 0.39 (0.34) 100.0 % 0.60 [ 0.42, 0.79 ]
Total (95% CI) 202 297 100.0 % 0.60 [ 0.42, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.46 (P < 0.00001)
-1 -0.5 0 0.5 1
Favours experimental Favours control
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A P P E N D I C E S
Appendix 1. MEDLINE, EMBASE and CINAHL search strategy
OVID MEDLINE OVID EMBASE CINAHL through EBSCOhost
Search terms for design
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized controlled trial.sh.
4. random allocation.sh.
5. double blind method.sh.
6. single blind method.sh.
7. clinical trial.pt.
8. exp clinical trial/
9. (clin$ adj25 trial$).ti,ab.
10. ((singl$ or doubl$ or trebl$ or tripl$)
adj25 (blind$ or mask$)).ti,ab.
11. placebos.sh.
12. placebo$.ti,ab.
13. random$.ti,ab.
14. research design.sh.
15. comparative study.sh.
16. exp evaluation studies/
17. follow up studies.sh.
18. prospective studies.sh.
19. (control$ or prospectiv$ or volun-
teer$).ti,ab.
Search terms for design
1. randomized controlled trial.sh.
2. randomization.sh.
3. double blind procedure.sh.
4. single blind procedure.sh.
5. exp clinical trials/
6. (clin$ adj25 trial$).ti,ab.
7. ((singl$ or doubl$ or trebl$ or tripl$)
adj25 (blind$ or mask$)).ti,ab.
8. placebo.sh.
9. placebo$.ti,ab.
10. random$.ti,ab.
11. methodology.sh.
12. comparative study.sh.
13. exp evaluation studies/
14. follow up.sh.
15. prospective study.sh.
16. (control$ or prospectiv$ or volun-
teer$).ti,ab.
Search terms for design
1. (MH “Clinical Trials+”)
2. (MH “Random Assignment”)
3. (MH “Double-Blind Studies”) or (MH
“Single-Blind Studies”)
4. TX (clin$ n25 trial$)
5. TX (sing$ n25 blind$)
6. TX (sing$ n25 mask$)
7. TX (doubl$ n25 blind$)
8. TX (doubl$ n25 mask$)
9. TX (trebl$ n25 blind$)
10. TX (trebl$ n25 mask$)
11. TX (tripl$ n25 blind$)
12. TX (tripl$ n25 mask$)
13. (MH “Placebos”)
14. TX placebo$
15. TX random$
16. (MH “Study Design+”)
17. (MH “Comparative Studies”)
18. (MH “Evaluation Research”)
19. (MH “Prospective Studies+”)
20. TX (control$ or prospectiv$ or volun-
teer$)
21. S1 or S2 or (…….) or S20
Search terms for Osteoarthritis
20. exp osteoarthritis/
21. osteoarthriti$.ti,ab,sh.
22. osteoarthro$.ti,ab,sh.
23. gonarthriti$.ti,ab,sh.
24. gonarthro$.ti,ab,sh.
25. coxarthriti$.ti,ab,sh.
26. coxarthro$.ti,ab,sh.
27. arthros$.ti,ab.
28. arthrot$.ti,ab.
29. ((knee$ or hip$ or joint$) adj3 (pain$
or ach$ or discomfort$)).ti,ab.
30. ((knee$ or hip$ or joint$) adj3
stiff$).ti,ab.
Search terms for Osteoarthritis
17. exp osteoarthritis/
18. osteoarthriti$.ti,ab,sh.
19. osteoarthro$.ti,ab,sh.
20. gonarthriti$.ti,ab,sh.
21. gonarthro$.ti,ab,sh.
22. coxarthriti$.ti,ab,sh.
23. coxarthro$.ti,ab,sh.
24. arthros$.ti,ab.
25. arthrot$.ti,ab.
26. ((knee$ or hip$ or joint$) adj3 (pain$
or ach$ or discomfort$)).ti,ab.
27. ((knee$ or hip$ or joint$) adj3
stiff$).ti,ab.
Search terms for Osteoarthritis
22. osteoarthriti$
23. (MH “Osteoarthritis”)
24. TX osteoarthro$
25. TX gonarthriti$
26. TX gonarthro$
27. TX coxarthriti$
28. TX coxarthro$
29. TX arthros$
30. TX arthrot$
31. TX knee$ n3 pain$
32. TX hip$ n3 pain$
33. TX joint$ n3 pain$
34. TX knee$ n3 ach$
35. TX hip$ n3 ach$
36. TX joint$ n3 ach$
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(Continued)
37. TX knee$ n3 discomfort$
38. TX hip$ n3 discomfort$
39. TX joint$ n3 discomfort$
40. TX knee$ n3 stiff$
41. TX hip$ n3 stiff$
42. TX joint$ n3 stiff$
43. S22 or S23 or S24….or S42
Search terms for Opioids
31. exp Analgesics, Opioid/
32. exp Narcotics/
33. acetyldihydrocodeine.tw.
34. alfentanil.tw.
35. allylprodine.tw.
36. alphamethylfentanyl.tw.
37. alphaprodine.tw.
38. benzylmorphine.tw.
39. betaprodine.tw.
40. bezitriamide.tw.
41. buprenorphine.tw.
42. butorphanol.tw.
43. bremazocine.tw.
44. carfentan$.tw.
45. codeine.tw.
46. contin.tw.
47. dextromoramide.tw.
48. dextropropoxyphene.tw.
49. dezocine.tw.
50. diacetylmorphine.tw.
51. diamorphine.tw.
52. dihydrocodeine.tw.
53. dihydromorphine.tw.
54. dihydromorphone.tw.
55. diphenoxylate.tw.
56. dipipanone.tw.
57. enadoline.tw.
58. ethylketazocine.tw.
59. ethylmorphine.tw.
60. etonitazene.tw.
61. etorphine.tw.
62. fentanyl.tw.
63. heroin.tw.
64. hydrocodone.tw.
65. hydromorphin$.tw.
66. hydromorphone.tw.
Search terms for Opioids
28. exp Analgesics, Opioid/
29. exp Narcotic Analgesic Agent/
30. acetyldihydrocodeine.tw.
31. alfentanil.tw.
32. allylprodine.tw.
33. alphamethylfentanyl.tw.
34. alphaprodine.tw.
35. benzylmorphine.tw.
36. betaprodine.tw.
37. bezitriamide.tw.
38. buprenorphine.tw.
39. butorphanol.tw.
40. bremazocine.tw.
41. carfentan$.tw.
42. codeine.tw.
43. contin.tw.
44. dextromoramide.tw.
45. dextropropoxyphene.tw.
46. dezocine.tw.
47. diacetylmorphine.tw.
48. diamorphine.tw.
49. dihydrocodeine.tw.
50. dihydromorphine.tw.
51. dihydromorphone.tw.
52. diphenoxylate.tw.
53. dipipanone.tw.
54. enadoline.tw.
55. ethylketazocine.tw.
56. ethylmorphine.tw.
57. etonitazene.tw.
58. etorphine.tw.
59. fentanyl.tw.
60. heroin.tw.
61. hydrocodone.tw.
62. hydromorphin$.tw.
63. hydromorphone.tw.
Search terms for Opioids
44. MH “ Analgesics, Opioid”
45. MH “Narcotics”
46. TX acetyldihydrocodeine
47. TX alfentanil
48. TX allylprodine
49. TX alphamethylfentanyl
50. TX alphaprodine
51. TX benzylmorphine
52. TX betaprodine
53. TX bezitriamide
54. TX buprenorphine
55. TX butorphanol
56. TX bremazocine
57. TX carfentan$
58. TX codeine
58. TX contin
60. TX dextromoramide
61. TX dextropropoxyphene
62. TX dezocine
63. TX diacetylmorphine
64. TX diamorphine
65. TX dihydrocodeine
66. TX dihydromorphine
67. TX dihydromorphone
68. TX diphenoxylate
69. TX dipipanone
70. TX enadoline
71. TX ethylketazocine
72. TX ethylmorphine
73. TX etonitazene
74. TX etorphine
75. TX fentanyl
76. TX heroin
77. TX hydrocodone
78. TX hydromorphin$
79. TX hydromorphone
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(Continued)
67. ketazocine.tw.
68. ketobemidone.tw.
69. lefetamine.tw.
70. levomethadon.tw.
71. levomethadyl.tw.
72. levomethorphan$.tw.
73. levorphanol.tw.
74. loperamide.tw.
75. meperidine.tw.
76. meptazinol.tw.
77. methadone.tw.
78. methadyl.tw.
79. methylmorphine.tw.
80. morphin$.tw.
81. nalbuphine.tw.
82. narcotic$.tw.
83. nicocodeine.tw.
84. nicomorphine.tw.
85. normorphine.tw.
86. noscapin$.tw.
87. ohmefentanyl.tw.
88. opiate$.tw.
89. opioid$.tw.
90. opium.tw.
91. oripavine.tw.
92. oxycodone.tw.
93. oxycontin.tw.
94. oxymorphone.tw.
95. papaveretum.tw.
96. papaverin.tw.
97. pentazocine.tw.
98. percocet.tw.
99. peronine.tw.
100. pethidine.tw.
101. phenazocine.tw.
102. phencyclidine.tw.
103. pholcodine.tw.
104. piritramid$.tw.
105. prodine.tw.
106. promedol.tw.
107. propoxyphene.tw.
108. remifentanil.tw.
109. sufentanil.tw.
110. tapentadol.tw.
111. thebaine.tw.
112. tilidine.tw.
64. ketazocine.tw.
65. ketobemidone.tw.
66. lefetamine.tw.
67. levomethadon.tw.
68. levomethadyl.tw.
69. levomethorphan$.tw.
70. levorphanol.tw.
71. loperamide.tw.
72. meperidine.tw.
73. meptazinol.tw.
74. methadone.tw.
75. methadyl.tw.
76. methylmorphine.tw.
77. morphin$.tw.
78. nalbuphine.tw.
79. narcotic$.tw.
80. nicocodeine.tw.
81. nicomorphine.tw.
82. normorphine.tw.
83. noscapin$.tw.
84. ohmefentanyl.tw.
85. opiate$.tw.
86. opioid$.tw.
87. opium.tw.
88. oripavine.tw.
89. oxycodone.tw.
90. oxycontin.tw.
91. oxymorphone.tw.
92. papaveretum.tw.
93. papaverin.tw.
94. pentazocine.tw.
95. percocet.tw.
96. peronine.tw.
97. pethidine.tw.
98. phenazocine.tw.
99. phencyclidine.tw.
100. pholcodine.tw.
101. piritramid$.tw.
102. prodine.tw.
103. promedol.tw.
104. propoxyphene.tw.
105. remifentanil.tw.
106. sufentanil.tw.
107. tapentadol.tw.
108. thebaine.tw.
109. tilidine.tw.
80. TX ketazocine
81. TX ketobemidone
82. TX lefetamine
83. TX levomethadon
84. TX levomethadyl
85. TX levomethorphan$
86. TX levorphanol
87. TX loperamide
88. TX meperidine
89. TX meptazinol
90. TX methadone
91. TX methadyl
92. TX methylmorphine
93. TX morphin$
94. TX nalbuphine
95. TX narcotic$
96. TX nicocodeine
97. TX nicomorphine
98. TX normorphine
99. TX noscapin$
100. TX ohmefentanyl
101. TX opiate$
102. TX opioid$
103. TX opium
104. TX oripavine
105. TX oxycodone
106. TX oxycontin
107. TX oxymorphone
108. TX papaveretum
109. TX papaverin
110. TX pentazocine
111. TX percocet
112. TX peronine
113. TX pethidine
114. TX phenazocine
115. TX phencyclidine
116. TX pholcodine
117. TX piritramid$
118. TX prodine
119. TX promedol
120. TX propoxyphene
121. TX remifentanil
122. TX sufentanil
123. TX tapentadol
124. TX thebaine
125. TX tilidine
126. S44 or S45 or S125
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Combining terms
113. or/31-112
114. or/1-19
115. or/20-30
116. and/113-115
117. animal/
118. animal/ and human/
119. 117 not 118
120. 116 not 119
121. remove duplicates from 120
Combining terms
110. or/28-109
111. or/1-16
112. or/17-27
113. and/110-112
114. animal/
115. animal/ and human/
116. 114 not 115
117. 113 not 116
118. remove duplicates from 117
Combining terms
127. S21 and S43 and S126
62Oral or transdermal opioids for osteoarthritis of the knee or hip (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 2. CENTRAL search strategy
CENTRAL
Search terms for Osteoarthritis
#1. MeSH descriptor Osteoarthritis explode all trees
#2. (osteoarthritis* OR osteoarthro* OR gonarthriti* OR gonarthro*
OR coxarthriti* OR coxarthro* OR arthros* OR arthrot* OR
((knee* OR hip* OR joint*) near/3 (pain* OR ach* OR discomfort*))
OR ((knee* OR hip* OR joint*) near/3 stiff*)) in Clinical Trials
Search terms for Opioids
#3. MeSH descriptor Analgesics, Opioid explode all trees
#4. MeSH descriptor Narcotics explode all trees
#5. (acetyldihydrocodeine OR alfentanil OR allylprodine OR
alphamethylfentanyl OR alphaprodine OR benzylmorphine OR
betaprodine OR bezitriamide OR buprenorphine OR butorphanol
OR bremazocine OR carfentan* OR codeine OR contin OR
dextromoramide OR dextropropoxyphene OR dezocine OR
diacetylmorphine OR diamorphine OR dihydrocodeine OR
dihydromorphine OR dihydromorphone OR diphenoxylate OR
dipipanone OR enadoline OR ethylketazocine OR ethylmorphine OR
etonitazene OR etorphine OR fentanyl OR heroin OR hydrocodone
OR hydromorphin* OR hydromorphone OR ketazocine OR
ketobemidone OR lefetamine OR levomethadon OR levomethadyl
OR levomethorphan* OR levorphanol OR loperamide OR
meperidine OR meptazinol OR methadone OR methadyl OR
methylmorphine OR morphin* OR nalbuphine OR narcotic* OR
nicocodeine OR nicomorphine OR normorphine OR noscapin* OR
ohmefentanyl OR opiate* OR opioid* OR opium OR oripavine OR
oxycodone OR oxycontin OR oxymorphone OR papaveretum OR
papaverin OR pentazocine OR percocet OR peronine OR pethidine
OR phenazocine OR phencyclidine OR pholcodine OR piritramid*
OR prodine OR promedol OR propoxyphene OR remifentanil OR
sufentanil OR tapentadol OR thebaine OR tilidine) in Clinical Trials
Combining terms
#6. (#1 OR #2)
#7. (#3 OR #4 OR #5)
#8. (#6 AND #7) in Clinical Trials
WH A T ’ S N E W
Last assessed as up-to-date: 12 May 2008.
13 May 2008 Amended Change in authorship
1 May 2008 Amended CMSG ID C141-R
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The cut off to distinguish between short-term and long-term trials was changed from 26 weeks to one month.
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